Growing Need for Early Detection & Prevention of Neurological Diseases Driving Neurogenomics Research

Neurogenomics is the examination of how the gene contributes to the structure, function, and development of the nervous system. It involves investigations of how genome products (proteomes and transcriptomes) vary in space and time. Neurogenomics diverges significantly from the application of genetic sciences to other systems, mainly in the spatial category, as connectivity and anatomy are principal to understanding the functioning of the nervous system.

Globally, migraine, neonatal encephalopathy (brain injury), stroke, and diabetic neuropathy (nerve damage), as well as Alzheimer’s disease and other dementias, are major contributors to neurological health loss. In 2021, pediatric and neurodevelopmental conditions were expected to collectively account for approximately a fifth of the global neurological burden, equivalent to 80 million years of healthy life lost. Diabetic neuropathy was the fastest-growing neurological condition. The number of individuals with diabetic neuropathy more than tripled compared to 1990, reaching 206 million cases in 2021 globally. This increase was based on the worldwide increase in diabetes. Furthermore, other conditions, such as neurological complications from COVID-19, including cognitive impairment and Guillain-Barré syndrome, that previously did not exist, now account for over 23 million cases (Source: World Health Organization, March 2024 Report).

In 2021, central and western sub-Saharan Africa were the regions with the highest nervous system burden, while high-income Asia-Pacific and Australasia had the lowest burden. According to a major analysis from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet Neurology journal, in 2021, 3.4 billion people were affected by nervous system conditions. Thus, the rising prevalence of neurological disorders is expected to boost the demand for advanced neurological solutions, driving the growth of the neurogenomics market.

Active Research in Genomics and Proteomics

During the last decade, active research in genomics and proteomics has increased, mainly due to technological advancements and the need to understand the genetic and molecular makeup of various neurological diseases. Traditionally, conventional technologies such as Sanger’s, which could sequence and analyze single genes, amplicon targets, genomic fragments, and short tandem repeats, were used in proteomics and genomics research. However, according to the National Human Genome Research Institute, Sanger sequencing can produce inaccurate results in many cases, provide low throughput, and be time-consuming. Hence, it has recently been replaced by Next-generation Sequencing (NGS), which can analyze 100 genes simultaneously, needs a low amount of input, and is significantly more cost-effective. Sanger sequencing costs about USD 500 per 1,000 bases, whereas NGS costs USD 0.50 per 1,000 bases. Moreover, the use of NGS in neurogenomics studies has enabled researchers to accurately identify disease genes, improve diagnosis, screen for gene mutations, and provide genetic counselling, among others. Thus, active research in genomics and proteomics is increasing the demand for advanced clinical & research solutions to obtain more precise and fruitful insights for neurogenomics studies.

Neurogenomics Market Analysis

Recent insights from Meticulous Research^® provide valuable perspectives on the future trajectory of the Global Neurogenomics Industry. Projections suggest a potential worth of $4.68 billion by 2031, driven by a remarkable Compound Annual Growth Rate (CAGR) of 16.6% from 2024 to 2031.

Notably, influential industry players, including Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), MGI Tech Co., Ltd. (China), F. Hoffmann-La Roche Ltd. (Switzerland), and Revvity, Inc. (U.S.) and other major players have established a broad presence across various regions, leading to the widespread adoption of their consumables and instruments for several diagnostics and research purposes. In essence, this comprehensive overview from Meticulous Research serves as a gateway into the neurogenomics market.

Conclusion

The rising focus on genomics studies globally has propelled the demand for advanced neurogenomics solutions. Additionally, diagnoses of neurological diseases facilitated using advanced technologies are reshaping treatment approaches for several neurological conditions, making them more effective and precise.

Access Full Report Here @ https://www.meticulousresearch.com/product/neurogenomics-market-6019